ATNM-400 Demonstrates Superior Lung Cancer Efficacy
🕓 Estimated Reading Time: 5 minutes Overview Actinium Pharmaceuticals, Inc. has announced groundbreaking preclinical data for its novel therapeutic candidate, ATNM-400 lung cancer , showcasing superior anti-tumor activity compared to existing leading treatments for EGFR-mutant non-small cell lung cancer (NSCLC). The findings, presented at the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, highlight ATNM-400's potential to redefine treatment strategies for patients with this aggressive form of cancer. The data also revealed a significant mechanistic and synergistic effect when ATNM-400 was combined with osimertinib, a widely used third-generation EGFR inhibitor, suggesting a powerful new combination therapy approach. Background & Context Lung cancer remains a leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases. A significant subset of NSCLC patie...